In clinical trials
Skin & aging
LTX-315
Evidence
Clinical trials
Class
Oncolytic host-defense peptide
KEY TAKEAWAY
LTX-315 is a short synthetic peptide modeled on lactoferricin, a natural antimicrobial peptide. It was designed to be injected directly into tumors. LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.
Written by the Veylo editorial team · Updated
November 2026
What it is
Oncolytic host-defense peptide
Being studied for
Studied as an injection into solid tumors, alone and with immunotherapy
Key fact
LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.
Route
Injected directly into tumors in trials
Evidence strength
Clinical trials
LTX-315 is a short synthetic peptide modeled on lactoferricin, a natural antimicrobial peptide. It was designed to be injected directly into tumors.
It disrupts the membranes of cancer cells, causing them to burst and release tumor antigens that can prime the immune system.
LTX-315 is not FDA-approved and has only been tested in early-phase clinical trials.
Studied as an injection into solid tumors, alone and with immunotherapy.
Early trials reported injection-site reactions and other effects. Safety is still being evaluated.
LTX-315: see PubMed and ClinicalTrials.gov for published studies and registered trials. No FDA drug label exists for the uses described.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.